ACER THERAPEUTICS INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-04-01: Study NCT06069375; Company role Collaborator; Phase Phase 2; Status Suspended.
- 2022-11-07: Study NCT05432466; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2022-03-30: Study NCT05325775; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Completed.
- 2012-08: Study NCT01684761; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-04-01 | NCT06069375 Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) | Collaborator Lead: Jerry Vockley, MD, PhD | Phase 2 | Suspended | Medium-chain Acyl-CoA Dehydrogenase Deficiency | 24 | 2028-12 |
| 2022-11-07 | NCT05432466 Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome | Lead sponsor | Phase 3 | Recruiting | Vascular Ehlers-Danlos Syndrome | 150 | 2029-04-01 |
| 2022-03-30 | NCT05325775 Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Post-menopausal Vasomotor Symptoms | 49 | 2023-03-04 |
| 2012-08 | NCT01684761 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis | Lead sponsor | Phase 2 | Completed | Autoimmune Diseases of the Nervous System; Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Disease Progression; Brain Atrophy | 183 | 2016-10 |
| 2007-11 | NCT00595920 Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis | Lead sponsor | Phase 2 | Terminated Results posted | Multiple Sclerosis, Relapsing-Remitting; Clinically Isolated Syndrome | 116 | 2008-12 |
| 2006-05 | NCT00245622 Autologous T Cell Vaccine (TCV) for Multiple Sclerosis | Lead sponsor | Phase 2 | Completed | Relapsing-Remitting Multiple Sclerosis | 150 | 2008-09 |
| 2002-07 | NCT00587691 Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis | Lead sponsor | Phase 1, Phase 2 | Completed | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis, Secondary Progressive | 16 | 2008-12 |